Thermo Fisher Scientific filings document operating results, material agreements, governance matters and capital-structure disclosures for a global supplier of scientific instruments, laboratory products, diagnostics, life science tools and pharmaceutical services. Recent Form 8-K reports include quarterly and annual results, acquisition-related events and definitive agreements.
The company’s proxy materials cover shareholder voting and board-governance matters. Its securities disclosures identify common stock and multiple NYSE-listed senior note classes, while Form 25 filings document removal from listing and registration for specific senior notes. The filing record also includes risk-factor and corporate disclosure categories tied to Thermo Fisher’s operating businesses and financing structure.
THERMO FISHER SCIENTIFIC INC. (TMO) reported an insider equity transaction by Lisa P. Britt, Sr. VP and Chief HR Officer. On August 19, 2026, she exercised stock options for 11,440 shares of common stock at an exercise price of $418.32 per share and then sold 11,440 shares of common stock at a weighted average price of $613.12 per share, with individual sale prices ranging from $613.09 to $613.49.
THERMO FISHER SCIENTIFIC INC. (TMO) officer Lisa P. Britt has filed a Rule 144 notice for a planned sale of up to 11,440 shares of common stock through Fidelity Brokerage Services LLC on the NYSE, with an aggregate market value of about $7.01 million. Shares were acquired via a stock option exercise for cash. In the prior three months, Britt sold 5,850 shares for proceeds of $3,393,000.
Thermo Fisher Scientific Executive Vice President Michael D. Shafer reported option exercises and stock sales. On August 11, 2026, he exercised options for 25,500 shares of common stock at strike prices of $309.63 and $418.32 per share and acquired the same number of shares. He then sold 25,500 shares at $600.00 per share pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025. A footnote states his holdings include an additional 44.079 shares acquired under the employee stock purchase plan on May 15, 2026, and the options exercised had vested in four equal installments from February 25, 2021 through February 25, 2024.
THERMO FISHER SCIENTIFIC INC. executive Joseph R. Holmes, VP & Chief Accounting Officer, exercised stock options for 420 shares of common stock at an exercise price of $309.63 per share on August 7, 2026, and sold 420 shares at $584.81 per share the same day. Following the option exercise, he reported 140 stock options remaining from this grant, which expires on February 25, 2027.
THERMO FISHER SCIENTIFIC INC. Chairman & CEO Marc N. Casper reported exercising options for 275 shares of common stock at an exercise price of $309.63 per share, leaving 20,275 option shares outstanding. On the same date, entities associated with him sold 4,883 common shares, through multiple open-market transactions at weighted average prices generally between $577.37 and $593.36 per share, including sales by Floral Park Associates, Inc. The trades were effected under a Rule 10b5-1 trading plan adopted on April 27, 2026. Indirect holdings include 5,000 shares held by MNC 2020 Irrevocable Trust and 11,300 shares held by Alison Casper 2020 Irrevocable Trust, for which Casper disclaims beneficial ownership except to any pecuniary interest.
Thermo Fisher Scientific executive Lisa P. Britt, Sr. VP and Chief HR Officer, exercised stock options for 5850.0000 shares of common stock at an exercise price of $309.6300 per share on August 6, 2026, then sold 5850.0000 shares at $580.0000 per share the same day. The option, covering 5850.0000 shares and originally expiring on 2027-02-25, had vested in four equal installments from 2021 through 2024 and is now fully exercised with no remaining derivative position.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised stock options for 10,000 shares of common stock at an exercise price of $309.63 per share on August 6, 2026, then, under a Rule 10b5-1 trading plan adopted April 27, 2026, sold an aggregate 15,000 common shares in multiple transactions at weighted-average prices generally between the low $570s and high $570s, both directly and indirectly through Floral Park Associates, Inc. The exercised option, which vested in four equal installments from 2021–2024, expires on February 25, 2027, and 20,550 options remain outstanding afterward.
Thermo Fisher Scientific Chairman & CEO Marc N. Casper exercised 10,000 stock options at $309.63 per share on August 5, 2026, acquiring an equal number of common shares, and then, together with an affiliated entity, sold 15,000 shares at weighted‑average prices between $565.86 and $577.63 under a Rule 10b5‑1 trading plan adopted April 27, 2026. The exercised option grant now shows 30,550 options remaining, expiring February 25, 2027.